CureVac has reported that the ongoing Phase I study of its Covid-19 vaccine candidate CVnCoV showed that it was well-tolerated across all tested doses ranging from 2 to 12µg and induced strong binding and neutralising antibody responses.

The Phase I study is evaluating the safety, reactogenicity and immunogenicity of the investigational vaccine CVnCoV, an optimised, non-chemically modified mRNA that encodes the prefusion stabilised full-length spike protein of the SARS-CoV-2 virus.

Its mode of action imitates the natural immune response to the Covid-19 infection observed in recovered patients.

The Phase I dose-escalation study has so far enrolled over 250 healthy subjects aged 18 to 60.

Participants were vaccinated intramuscularly with CVnCoV at escalating dose levels of 2µg, 4µg, 6µg, 8µg and 12µg on days one and 29.

For every dose level, the trial had up to ten Covid-19 positive participants to further evaluate the safety and immunogenicity of the vaccine candidate in this sub-population.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Early data from the trial showed indications of functional T cells confirming the activation of cellular immune response, with the analysis of T cell-mediated immunity progressing.

Immunogenicity data demonstrated the induction of binding antibody titers, translating into relevant virus titers, neutralising antibodies at all tested dose levels.

CureVac chief technology officer Dr Mariola Fotin-Mleczek said: “These initial data show a robust and highly efficient immune response to our natural mRNA-based CVnCoV vaccine candidate, including antibody and initial T cell responses at the level of a relevant panel of symptomatic convalescent patients.

“We are grateful to all study volunteers who are helping to enable the development of a vaccine that will provide the best possible protection for people.”

The trial data supports the use of a 12µg dose of CVnCoV for the upcoming Phase IIb/III study.

In September, CureVac initiated the dosing of participants in a Phase IIa trial of CVnCoV. The dose-confirmation study on 690 healthy participants aged 61 or above and those aged 18-60 is progressing in Peru and Panama.